» Authors » Ying-Chun Shen

Ying-Chun Shen

Explore the profile of Ying-Chun Shen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 47
Citations 898
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu S, Lin S, Lo H, Tang S, Hsu Y, Peng Y, et al.
Small . 2025 Mar; :e2412549. PMID: 40045595
Rechargeable nickel-ion batteries (RNiBs) have attracted significant attention because of their high volumetric density, low cost, environmental friendliness, and easy recyclability. In this study, a rechargeable nickel-iodine battery using a...
2.
Giannatempo P, Machiels J, Sassa N, Arranz J, Fujii Y, Su W, et al.
Clin Genitourin Cancer . 2025 Mar; 23(2):102273. PMID: 40037029
Introduction: A post hoc analysis of efficacy and safety outcomes with pembrolizumab monotherapy was conducted in patients with advanced or metastatic urothelial carcinoma (UC) with pure transitional cell carcinoma (TCC)...
3.
Shen Y, Chang N, Yeh C, Lin W, Wei M, Ou D, et al.
J Immunother Cancer . 2025 Feb; 13(2). PMID: 39979068
Background And Aims: Corticosteroid is effective in alleviating immune-related adverse events (irAEs) of immune checkpoint blockade (ICB). However, prophylactic use of corticosteroid to prevent irAEs is not recommended due to...
4.
Liu T, Chen S, Rau K, Lu L, Lin P, Su Y, et al.
Liver Cancer . 2024 Oct; 13(5):509-521. PMID: 39435270
Introduction: The progression patterns, dispositions, and outcomes of patients with advanced hepatocellular carcinoma (HCC) who achieved durable responses with immunotherapy remain poorly characterized. Methods: Patients with advanced HCC who received...
5.
Shen Y, Liu T, Nicholas A, Soyama A, Yuan C, Chen T, et al.
J Clin Oncol . 2024 Aug; 42(34):4060-4070. PMID: 39197119
Purpose: Durable partial response (PR) and durable stable disease (SD) are often seen in patients with hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab (atezo-bev). This study investigates the outcome of...
6.
Chen B, Liang P, Shih T, Liu T, Shen Y, Lu L, et al.
J Hepatocell Carcinoma . 2024 Jun; 11:1015-1029. PMID: 38854818
Purpose: We investigated whether spleen volume (SV) changes were associated with treatment outcomes in advanced hepatocellular carcinoma (HCC) patients who received immunotherapy or first-line sorafenib. Patients And Methods: Patients with...
7.
Huang D, Liao B, Hsu W, Yang C, Lin Y, Wu S, et al.
Oncology . 2023 Oct; 102(4):318-326. PMID: 37778345
Introduction: In real-world practice, most non-small cell lung cancer (NSCLC) patients receiving combined immunochemotherapy are exposed to short-course corticosteroids following immune checkpoint inhibitor (ICI) infusion to prevent chemotherapy-related adverse events....
8.
Peng S, Lin C, Chen I, Shen Y, Chang D, Chen T, et al.
Cancer Med . 2023 Sep; 12(19):20035-20051. PMID: 37737544
Background: Immune checkpoint inhibitors have revolutionized the treatment of malignancies. However, disproportionate enrollment among races and ethnicities places the generalizability of global trial results in doubt. Methods: In this systematic...
9.
Chaudhary M, Shih Y, Tang S, Yang T, Kuo T, Chung C, et al.
ACS Appl Mater Interfaces . 2023 Jul; 15(28):33858-33867. PMID: 37428508
Here, we propose phase and interfacial engineering by inserting a functional WO layer and selenized it to achieve a 2D-layered WSe/WO heterolayer structure by a plasma-assisted selenization process. The 2D-layered...
10.
Shen Y, Lee C, Wang H, Kao M, Hou P, Chen Y, et al.
ACS Nano . 2023 Jan; 17(3):2019-2028. PMID: 36689417
Flexible optoelectronics have garnered considerable interest for applications such as optical communication, motion capture, biosignal detection, and night vision. Transition-metal dichalcogenides are widely used as flexible photodetectors owing to their...